Figure 1: Morphology of (A) gliclazide, (B) PVP K-30,[14] (C) PEG 6000,[15] (D) physical mixture, (E) F1, (F) F2, (G) F3, (H) F4, and (I) F5
![Figure 1: Morphology of (A) gliclazide, (B) PVP K-30,<sup>[14]</sup> (C) PEG 6000,<sup>[15]</sup> (D) physical mixture, (E) F1, (F) F2, (G) F3, (H) F4, and (I) F5](articles/2019/11/3/images/JPharmBioallSci_2019_11_3_262_262200_f1.jpg)
| Close | |
|
|
|
|
Figure 1: Morphology of (A) gliclazide, (B) PVP K-30,[14] (C) PEG 6000,[15] (D) physical mixture, (E) F1, (F) F2, (G) F3, (H) F4, and (I) F5
|
|